3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
1
Interventions
pembrolizumab
137
Nivolumab
116
Ipilimumab
68
Cyclophosphamide
33
Specimen Handling
31
Magnetic Resonance Spectroscopy
28
trametinib
23
binimetinib
22
fludarabine
21
Interleukin-2
20
dabrafenib
19
relatlimab
17
encorafenib
17
Biopsy
17
CTLA-4 Antigen
16
cemiplimab
15
atezolizumab
15
aldesleukin
15
Radiosurgery
15
fludarabine phosphate
14
Opdualag
14
Radiotherapy
11
lenvatinib
10
Blood Specimen Collection
10
lifileucel
9
Paclitaxel
8
Cisplatin
8
Bevacizumab
8
spartalizumab
7
cobimetinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Biological Factors
×
1 year
×
Clear all
NCT02645149
2026-05-29
Match Mel
Melanoma Institute Australia
Phase 2
Completed
216 enrolled